AEMD (Aethlon Medical) ROCE % : -473.25% (As of Mar. 2025)

View and export this data going back to 1998. Start your Free Trial

What is Aethlon Medical ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Aethlon Medical's annualized ROCE % for the quarter that ended in Mar. 2025 was -473.25%.

Aethlon Medical ROCE % Historical Data

The historical data trend for Aethlon Medical's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aethlon Medical ROCE % Chart

Aethlon Medical Annual Data

Trend

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Mar25

ROCE %

Get a 7-Day Free Trial

-84.79

-77.51

-70.83

-112.73

-225.28

Aethlon Medical Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
ROCE %	Get a 7-Day Free Trial															-134.82	-133.54	-146.92	-128.87	-473.25

Aethlon Medical ROCE % Calculation

Aethlon Medical's annualized ROCE % for the fiscal year that ended in Mar. 2025 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Mar. 2025 )		(A: Mar. 2024 )		(A: Mar. 2025 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Mar. 2025 )		(A: Mar. 2024 )		(A: Mar. 2025 )
	=	-13.378	/	( ( (8.246 - 1.83)	+	(7.36 - 1.899) )	/ 2 )
	=	-13.378	/	( (6.416	+	5.461)	/ 2 )
	=	-13.378	/	5.9385
	=	-225.28 %

Aethlon Medical's ROCE % of for the quarter that ended in Mar. 2025 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2025 )		(Q: Dec. 2024 )		(Q: Mar. 2025 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2025 )		(Q: Dec. 2024 )		(Q: Mar. 2025 )
	=	-24.164	/	( ( (6.525 - 1.774)	+	(7.36 - 1.899) )	/ 2 )
	=	-24.164	/	( ( 4.751	+	5.461 )	/ 2 )
	=	-24.164	/	5.106
	=	-473.25 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2025) EBIT data.

Aethlon Medical (NAS:AEMD) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Aethlon Medical ROCE % Related Terms

Thank you for viewing the detailed overview of Aethlon Medical's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Aethlon Medical Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Aethlon Medical Inc (NAS:AEMD) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

11555 Sorrento Valley Road, Suite 203, San Diego, CA, USA, 92121

Website

https://www.aethlonmedical.com

Aethlon Medical Inc is a medical therapeutic company. The company is focused on addressing unmet needs in health and biodefense. The company is focused on the development of Hemopurifier, a clinical-stage therapeutic device designed to combat cancer and eliminate life-threatening viruses from the circulatory system.

Executives

Nicolas Gikakis	director	11555 SORRENTO VALLEY ROAD, SUITE 203, SAN DIEGO CA 92121
Lee D Arnold	officer: Chief Scientific Officer	C/O ASSEMBLY BIOSCIENCES, INC., 99 HUDSON STREET, 5TH FLOOR, NEW YORK NY 10013
Angela Rossetti	director	PALATIN TECHNOLOGIES, INC., 4B CEDAR BROOK DRIVE, CRANBURY NJ 08512
Steven P Larosa	officer: Chief Medical Officer	9635 GRANITE RIDGE DRIVE SUITE 100, SAN DIEGO CA 92123
Chetan Shah	director	9 GRACE HILL COURT, TITUSVILLE NJ 08560
Fisher Charles J Jr	director	C/O AETHLON MEDICAL, INC., 9635 GRANITE RIDGE DR., SUITE 100, SAN DIEGO CA 92123
Guy F. Cipriani	director	1727 EAGLERIDGE DRIVE, BELLINGHAM WA 98226
Sabrina Martucci Johnson	director	11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037
Rodell Timothy C Jr	officer: Interim CEO	201 MIDLAND AVE, ASPEN CO 81611
Weiner Family Revocable Trust Ellen R.	10 percent owner	10645 N. TATUM BOULEVARD, SUITE 200-166, PHOENIX AZ 85028
Phillip A Ward	director	8910 UNIVERSITY CENTER LANE #660, SAN DIEGO CA 92122
Thomas V Wornham	director	8910 UNIVERSITY CENTER LANE #660, SAN DIEGO CA 92122
Rodney S Kenley	director, officer: President	9635 GRANITE RIDGE DRIVE, SUITE 100, SAN DIEGO CA 92123
James B Frakes	officer: Chief Financial Officer	9635 GRANITE RIDGE DRIVE, SUITE 100, SAN DIEGO CA 92123
Barry Franklyn S Jr	director	1141 DELAWARE AVENUE #3N, BUFFALO NY 14209